May 11, 2022 / NTS GMT
Mats Hyttinge - Redeye AB - Analyst
Redeye welcomes Simon Grant, CEO of SciBase. Welcome, Simon, and please go ahead.
Simon Grant - SciBase Holding AB - CEO
Thank you, Mats. SciBase is based on Stockholm, and we are listed on NASDAQ First North. We work within dermatology -- disorders of the skin essentially, and we work with within dermatology and allergy. And these are interesting spaces because there's very little technology in these spaces today. And almost all diagnoses or a lot of diagnosis is done subjectively and visually. And this is where SciBase can add value.
Let's see if I can change. And now, sorry. So SciBase has a platform, and that platform can be used to evaluate the structure of the skin, and I'll take you through that. But there are three main areas to work with at the same platform, and we apply this to different indications.
The first indication: melanoma, this is the most dangerous skin cancer; and there's non-melanoma skin cancer, the other main type of skin cancer. And that is actually -- plus different skin cancers, but
SciBase Holding AB (publ) at Redeye Medtech & Diagnostics Seminar Transcript
May 11, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers